SG11201407110QA - Novel dosage form and formulation of abediterol - Google Patents
Novel dosage form and formulation of abediterolInfo
- Publication number
- SG11201407110QA SG11201407110QA SG11201407110QA SG11201407110QA SG11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA SG 11201407110Q A SG11201407110Q A SG 11201407110QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- barcelona
- abediterol
- llobregat
- laurea
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/178742 A1 (51) International Patent Classification: A61K 9/14 (2006.01) A61P11/08 (2006.01) A61K31/4706 (2006.01) A61P11/06 (2006.01) A61K9/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/061181 30 May 2013 (30.05.2013) English (30) Priority Data: 12382221.5 61/660,003 31 May 2012 (31.05.2012) 15 June 2012 (15.06.2012) English EP US (71) Applicant: ALMIRALL, S.A. [ES/ES]; Ronda del Gener al Mitre 151, E-08022 Barcelona (ES). (72) Inventors: ALLAIN RUIZ, Sandrine; C/O Laurea Miro 408-410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). SEOANE NUNEZ, Beatriz; C/O Laurea Miro 408- 410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). DE MIQUEL SERRA, Gonzalo; C/O Laurea Miro 408-410, Sant Feliu de Llobregat, E-08980 Barcelona (ES). (74) Agent: SRINIVASAN, Ravi Chandran; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) CJ •t l> 00 l> i-H ^ (54) Title: NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL 5 (57) Abstract: The present invention provides pharmaceutical a composition in the form of a dry powder for inhalation comprising C^l abediterol or a pharmaceutically acceptable salt in admixture with pharmaceutically acceptable carrier, a providing upon inhalation a dose equivalent to a metered nominal dose of about 1.25 or about 2.5 micrograms of free base abediterol administered with the Gen - (5T uair® inhaler. The present invention also provides said pharmaceutical composition for use in the treatment of respiratory disease 5- such as asthma and chronic obstructive pulmonary disease COPD.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382221.5A EP2668941A1 (en) | 2012-05-31 | 2012-05-31 | Novel dosage form and formulation of abediterol |
| US201261660003P | 2012-06-15 | 2012-06-15 | |
| PCT/EP2013/061181 WO2013178742A1 (en) | 2012-05-31 | 2013-05-30 | Novel dosage form and formulation of abediterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407110QA true SG11201407110QA (en) | 2014-12-30 |
Family
ID=46317311
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407110QA SG11201407110QA (en) | 2012-05-31 | 2013-05-30 | Novel dosage form and formulation of abediterol |
| SG10201913424SA SG10201913424SA (en) | 2012-05-31 | 2013-05-30 | Novel dosage form and formulation of abediterol |
| SG10201609119VA SG10201609119VA (en) | 2012-05-31 | 2013-05-30 | Novel dosage form and formulation of abediterol |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913424SA SG10201913424SA (en) | 2012-05-31 | 2013-05-30 | Novel dosage form and formulation of abediterol |
| SG10201609119VA SG10201609119VA (en) | 2012-05-31 | 2013-05-30 | Novel dosage form and formulation of abediterol |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150140099A1 (en) |
| EP (2) | EP2668941A1 (en) |
| JP (1) | JP6272836B2 (en) |
| KR (2) | KR20180104197A (en) |
| CN (1) | CN104394852A (en) |
| AR (1) | AR091233A1 (en) |
| AU (1) | AU2013269565B2 (en) |
| BR (1) | BR112014029735A2 (en) |
| CA (1) | CA2871358C (en) |
| CL (1) | CL2014003286A1 (en) |
| CO (1) | CO7141434A2 (en) |
| CR (1) | CR20140540A (en) |
| DO (1) | DOP2014000271A (en) |
| EA (1) | EA201401354A1 (en) |
| EC (1) | ECSP14028814A (en) |
| HK (1) | HK1203149A1 (en) |
| IL (1) | IL235831B (en) |
| IN (1) | IN2014DN08672A (en) |
| MX (1) | MX2014014350A (en) |
| MY (1) | MY184654A (en) |
| NI (1) | NI201400139A (en) |
| NZ (1) | NZ701261A (en) |
| PE (1) | PE20150171A1 (en) |
| PH (1) | PH12014502662A1 (en) |
| SG (3) | SG11201407110QA (en) |
| TW (1) | TWI610690B (en) |
| UY (1) | UY34838A (en) |
| WO (1) | WO2013178742A1 (en) |
| ZA (1) | ZA201407405B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| WO2014007781A2 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions |
| AU2015275933A1 (en) * | 2014-06-18 | 2017-02-02 | Cipla Limited | Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent |
| WO2019142214A1 (en) * | 2018-01-19 | 2019-07-25 | Cipla Limited | Pharmaceutical composition comprising tiotropium for inhalation |
| JP2021524323A (en) | 2018-05-22 | 2021-09-13 | シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ | Catheter insertion system and how to use it |
| CN112566550B (en) | 2018-08-10 | 2024-10-22 | C·R·巴德股份有限公司 | Automatic urine output measuring system and method thereof |
| US12083261B2 (en) | 2020-06-05 | 2024-09-10 | C. R. Bard, Inc. | Automated fluid output monitoring |
| US12055249B2 (en) | 2020-07-21 | 2024-08-06 | C. R. Bard, Inc. | Automatic fluid flow system with retractable connection |
| US11931151B2 (en) | 2020-12-22 | 2024-03-19 | C. R. Bard, Inc. | Automated urinary output measuring system |
| US12246146B2 (en) | 2020-12-23 | 2025-03-11 | C. R. Bard, Inc. | Automated weight based fluid output monitoring system |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT7920688V0 (en) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | INHALER FOR PULVERULENT MEDICINAL SUBSTANCES, WITH COMBINED DOSER FUNCTION. |
| CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| FI69963C (en) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | DOSERINGSANORDNING |
| DE3927170A1 (en) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | INHALATOR |
| IT1237118B (en) | 1989-10-27 | 1993-05-18 | Miat Spa | MULTI-DOSE INHALER FOR POWDER DRUGS. |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| DE4027391A1 (en) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | GAS-FREE INHALATION DEVICE |
| DE69129188T2 (en) | 1990-09-26 | 1998-07-30 | Pharmachemie B.V., Haarlem | INHALATOR WITH A RESERVOIR FOR MULTIPLE DOSED INHALATION AGENTS, WITH TRANSPORTATION DEVICE AND WITH A VERBAL CHAMBER |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE4239402A1 (en) | 1992-11-24 | 1994-05-26 | Bayer Ag | Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion |
| ES2128550T3 (en) | 1992-12-18 | 1999-05-16 | Schering Corp | INHALER FOR POWDERED MEDICINES. |
| DK0837710T3 (en) | 1995-06-21 | 2002-04-02 | Sofotec Gmbh & Co Kg | Pharmaceutical powder cartridge with integrated dosing device and powder inhaler inhaler |
| DE10129703A1 (en) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Atomizing system for a powder mixture and method for dry powder inhalers |
| ITMI20010357U1 (en) | 2001-06-28 | 2002-12-30 | Plastiape Spa | INHALER DEVICE |
| ES2195785B1 (en) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
| ES2211344B1 (en) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
| US20050148563A1 (en) * | 2003-09-26 | 2005-07-07 | Schering Corporation | Pulmonary disease treatment |
| ES2232306B1 (en) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| ES2251866B1 (en) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
| ES2251867B1 (en) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA. |
| CN1997418B (en) | 2004-07-16 | 2010-08-11 | 奥米罗有限公司 | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
| ES2265276B1 (en) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER. |
| ES2306595B1 (en) * | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 . |
| EP2100598A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| UY32297A (en) | 2008-12-22 | 2010-05-31 | Almirall Sa | MESILATE SALT OF 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLITOXI) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONA AS A RECEIVER AGONIST B (BETA ) 2 ACRENERGIC |
| EP2221297A1 (en) * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
| EP2221055A1 (en) * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
-
2012
- 2012-05-31 EP EP12382221.5A patent/EP2668941A1/en not_active Withdrawn
-
2013
- 2013-05-30 MX MX2014014350A patent/MX2014014350A/en unknown
- 2013-05-30 IN IN8672DEN2014 patent/IN2014DN08672A/en unknown
- 2013-05-30 PE PE2014002064A patent/PE20150171A1/en not_active Application Discontinuation
- 2013-05-30 TW TW102119230A patent/TWI610690B/en not_active IP Right Cessation
- 2013-05-30 CN CN201380028903.4A patent/CN104394852A/en active Pending
- 2013-05-30 CA CA2871358A patent/CA2871358C/en active Active
- 2013-05-30 SG SG11201407110QA patent/SG11201407110QA/en unknown
- 2013-05-30 EP EP13728344.6A patent/EP2854771A1/en not_active Withdrawn
- 2013-05-30 AU AU2013269565A patent/AU2013269565B2/en not_active Ceased
- 2013-05-30 MY MYPI2014703543A patent/MY184654A/en unknown
- 2013-05-30 WO PCT/EP2013/061181 patent/WO2013178742A1/en active Application Filing
- 2013-05-30 EA EA201401354A patent/EA201401354A1/en unknown
- 2013-05-30 KR KR1020187026487A patent/KR20180104197A/en not_active Ceased
- 2013-05-30 BR BR112014029735A patent/BR112014029735A2/en not_active Application Discontinuation
- 2013-05-30 NZ NZ701261A patent/NZ701261A/en not_active IP Right Cessation
- 2013-05-30 US US14/404,199 patent/US20150140099A1/en not_active Abandoned
- 2013-05-30 SG SG10201913424SA patent/SG10201913424SA/en unknown
- 2013-05-30 SG SG10201609119VA patent/SG10201609119VA/en unknown
- 2013-05-30 JP JP2015514503A patent/JP6272836B2/en not_active Expired - Fee Related
- 2013-05-30 KR KR1020147033563A patent/KR20150018526A/en not_active Ceased
- 2013-05-31 UY UY0001034838A patent/UY34838A/en not_active Application Discontinuation
- 2013-05-31 AR ARP130101927 patent/AR091233A1/en unknown
-
2014
- 2014-10-13 ZA ZA2014/07405A patent/ZA201407405B/en unknown
- 2014-11-20 IL IL235831A patent/IL235831B/en active IP Right Grant
- 2014-11-25 NI NI201400139A patent/NI201400139A/en unknown
- 2014-11-26 EC ECIEPI201428814A patent/ECSP14028814A/en unknown
- 2014-11-26 CR CR20140540A patent/CR20140540A/en unknown
- 2014-11-26 DO DO2014000271A patent/DOP2014000271A/en unknown
- 2014-11-27 CO CO14260864A patent/CO7141434A2/en unknown
- 2014-11-28 CL CL2014003286A patent/CL2014003286A1/en unknown
- 2014-11-28 PH PH12014502662A patent/PH12014502662A1/en unknown
-
2015
- 2015-04-16 HK HK15103713.3A patent/HK1203149A1/en unknown
-
2016
- 2016-06-30 US US15/198,289 patent/US20160303108A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407110QA (en) | Novel dosage form and formulation of abediterol | |
| SG11201909325RA (en) | 2-amino-quinoline derivatives | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201408292YA (en) | Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201407114YA (en) | Novel dosage and formulation | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408261UA (en) | Syringe | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201900471VA (en) | Combination therapy for copd | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof |